	ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
S23-PMC2821652	PMC2821652	2/2010	S23-PMC2821652	['THUS, in the Human fetus, Vitamin D Metabolism in all LIKELIHOOD begins with 25(Oh)D. as a result, the nutritional Vitamin D status of the Human fetus/neonate is totally DEPENDENT on the Vitamin D stores of the mother [11]; THUS, IF the mother is hypovitaminotic D, her fetus will experience depleted Vitamin D exposure throughout Gestation [14].']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 54), ('SUPERFICIAL_RELATIONSHIP', 170), ('PROBABLE_UNDERSTANDING', 224), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 230)]	5	[('NCBITaxon_9606', 'Homo sapiens', 13, 'human'), ('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 26, 'vitamin D metabolism'), ('CHEBI_71657', 'versiconol acetate', 77, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 139, 'human'), ('CHEBI_27300', 'vitamin D', 187, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 263, 'D'), ('CHEBI_27300', 'vitamin D', 301, 'vitamin D'), ('GO_0007565', 'female pregnancy', 331, 'gestation')]
S30-PMC2821652	PMC2821652	2/2010	S30-PMC2821652	['these aspects of Calcium and Vitamin D Metabolism are IMPORTANT in the understanding of Vitamin D sufficiency during Pregnancy and the PREMISE that the REQUIREMENTS of Vitamin D are stable throughout Gestation.']	[('IMPORTANT_CONSIDERATION', 54), ('INCOMPLETE_EVIDENCE', 135), ('IMPORTANT_CONSIDERATION', 152)]	3	[('GO_0051216', 'cartilage development', 17, 'calcium ...'), ('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 29, 'vitamin D metabolism'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('GO_0007565', 'female pregnancy', 117, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin D'), ('GO_0007565', 'female pregnancy', 200, 'gestation')]
S124-PMC2963768	PMC2963768	10/2010	S124-PMC2963768	['Vitamin A (41)\nGenetic polymorphisms in Genes encoding proteins INVOLVED in Vitamin D Metabolism, e.g.']	[('SUPERFICIAL_RELATIONSHIP', 64)]	1	[('CHEBI_27300', 'vitamin D', 0, 'vitamin A'), ('SO_0000704', 'gene', 15, 'Genetic'), ('SO_0000704', 'gene', 40, 'genes'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 76, 'vitamin D metabolism')]
S11-PMC2996405	PMC2996405	11/2010	S11-PMC2996405	['in addition we CONFIRM, at a molecular level, the LINK between schizophrenia and Vitamin D. finally, we discuss a MODEL in which schizophrenia is, at LEAST PARTLY, a maladaptive by-product of latitude DEPENDENT adaptive changes in Vitamin D Metabolism.']	[('INCOMPLETE_EVIDENCE', 15), ('SUPERFICIAL_RELATIONSHIP', 50), ('INCOMPLETE_EVIDENCE', 114), ('PROBABLE_UNDERSTANDING', 150), ('INCOMPLETE_EVIDENCE', 156), ('SUPERFICIAL_RELATIONSHIP', 201)]	6	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 231, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 231, 'vitamin D metabolism')]
S250-PMC2996405	PMC2996405	11/2010	S250-PMC2996405	['we also FOUND a molecular RELATIONSHIP of schizophrenia with both latitude and Vitamin D. AT LEAST in one case, our results SUGGEST that schizophrenia COULD BE a maladaptive by-product of latitude DEPENDENT adaptive changes in Vitamin D Metabolism.']	[('INCOMPLETE_EVIDENCE', 8), ('SUPERFICIAL_RELATIONSHIP', 26), ('PROBABLE_UNDERSTANDING', 90), ('INCOMPLETE_EVIDENCE', 124), ('INCOMPLETE_EVIDENCE', 151), ('SUPERFICIAL_RELATIONSHIP', 197)]	6	[('CHEBI_27300', 'vitamin D', 79, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 227, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 227, 'vitamin D metabolism')]
S56-PMC3075531	PMC3075531	7/2010	S56-PMC3075531	['Genes also CAN AFFECT Vitamin D Metabolism, skin color, and behavior, all of which CAN INFLUENCE circulating 25-Hydroxyvitamin D concentrations.']	[('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 15), ('INCOMPLETE_EVIDENCE', 83), ('SUPERFICIAL_RELATIONSHIP', 87)]	4	[('SO_0000704', 'gene', 0, 'Genes'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 22, 'vitamin D metabolism'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 109, '25-hydroxyvitamin D')]
S36-PMC3347028	PMC3347028	3/2012	S36-PMC3347028	['general Vitamin D Metabolism\nIN ORDER TO understand the DIFFERENCES between the nonpregnant and Pregnant states and their EFFECTS on Vitamin D Metabolism, it is ESSENTIAL to understand the nonpregnant state first.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 29), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 56), ('SUPERFICIAL_RELATIONSHIP', 122), ('IMPORTANT_CONSIDERATION', 161)]	4	[('CHEBI_28384', 'vitamin K', 8, 'Vitamin D'), ('GO_0046443', 'FAD metabolic process', 8, 'Vitamin D Metabolism'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 8, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 96, 'pregnant'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 133, 'vitamin D metabolism'), ('PR_000006444', 'diacylglycerol kinase delta', 141, 'D')]
S86-PMC3347028	PMC3347028	3/2012	S86-PMC3347028	['it is INTERESTING that during Pregnancy alone and at no other time during the Lifecycle there is an uncoupling of Vitamin D Metabolism from calcium such that by the end of the first trimester, 1,25(Oh)2D levels are more than double what they are during the nonpregnant state without concurrent changes in Serum calcium concentrations [6].']	[('ANOMALY_CURIOUS_FINDING', 6)]	1	"[('GO_0007565', 'female pregnancy', 30, 'pregnancy'), ('UBERON_0000104', 'life cycle', 78, 'lifecycle'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 114, 'vitamin D metabolism'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 195, '25(OH)2D'), ('UBERON_0001977', 'blood serum', 305, 'serum')]"
S59-PMC3395583	PMC3395583	7/2012	S59-PMC3395583	['figure3shows the direct RELATION between uvb radiation and Vitamin D status and the amount of time required for a change in uvb to IMPACT on Vitamin D Metabolism.']	[('SUPERFICIAL_RELATIONSHIP', 24), ('SUPERFICIAL_RELATIONSHIP', 131)]	2	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 141, 'vitamin D metabolism')]
S18-PMC3427192	PMC3427192	4/2012	S18-PMC3427192	['1,25(Oh)2D3, also referred to as Calcitriol, is then transported throughout the body via the Blood to various cells types that Express vdrs, where Gene Expression is induced.24,39BECAUSE the MAJORITY of Vitamin D Metabolism occurs in this skin, several FACTORS ARE THOUGHT TO INFLUENCE Vitamin D skin Metabolism, including age, body fat, the level of skin Melanin, and OTHER variables such as latitude, the amount and degree of sun exposure, and use of sunscreen products with uv protection.40these FACTORS HAVE BEEN PREVIOUSLY ASSOCIATED with Vitamin D deficiency in epidemiologic studies.41-43\n\ncaption (fig): figure 2.']	[('PROBABLE_UNDERSTANDING', 177), ('PROBABLE_UNDERSTANDING', 191), ('SUPERFICIAL_RELATIONSHIP', 253), ('INCOMPLETE_EVIDENCE', 261), ('INCOMPLETE_EVIDENCE', 265), ('SUPERFICIAL_RELATIONSHIP', 276), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 369), ('SUPERFICIAL_RELATIONSHIP', 499), ('INCOMPLETE_EVIDENCE', 507), ('INCOMPLETE_EVIDENCE', 517), ('SUPERFICIAL_RELATIONSHIP', 528)]	11	[('CHEBI_37958', 'dye', 0, '1,'), ('CHEBI_73394', 'Ala-Ser', 2, '25(OH)2D3'), ('CHEBI_17823', 'calcitriol', 33, 'calcitriol'), ('UBERON_0000178', 'blood', 93, 'blood'), ('GO_0010467', 'gene expression', 127, 'express'), ('GO_0010467', 'gene expression', 147, 'gene expression'), ('SO_0000704', 'gene', 147, 'gene'), ('CHEBI_27300', 'vitamin D', 203, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 203, 'vitamin D metabolism'), ('CHEBI_27300', 'vitamin D', 286, 'vitamin D'), ('GO_0008152', 'metabolic process', 301, 'metabolism'), ('CHEBI_25179', 'melanins', 356, 'melanin'), ('CHEBI_27300', 'vitamin D', 544, 'vitamin D')]
S0-PMC3470091	PMC3470091	9/2012	S0-PMC3470091	['the EFFICACY and SAFETY of a high dose of Vitamin D in mothers with Gestational diabetes mellitus: a randomized controlled clinical TRIAL\n\nabstract\nbackground: during Pregnancy and Lactation outstanding changes occur in mother’s Vitamin D Metabolism.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('IMPORTANT_CONSIDERATION', 17), ('QUESTION_ANSWERED_BY_THIS_WORK', 132)]	3	[('CHEBI_28384', 'vitamin K', 42, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 42, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 68, 'Gestational'), ('GO_0007565', 'female pregnancy', 167, 'pregnancy'), ('GO_0007595', 'lactation', 181, 'lactation'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 229, 'vitamin D metabolism')]
S99-PMC3476426	PMC3476426	8/2012	S99-PMC3476426	['Genetic polymorphisms of Cytochrome P450 enzymes HAVE also BEEN LINKED to autism, specifically Cyp27B1 that is ESSENTIAL for proper Vitamin D Metabolism.']	[('INCOMPLETE_EVIDENCE', 49), ('SUPERFICIAL_RELATIONSHIP', 64), ('IMPORTANT_CONSIDERATION', 111)]	3	[('SO_0000704', 'gene', 0, 'Genetic'), ('CHEBI_38557', 'cytochrome c2', 25, 'cytochrome P450'), ('PR_000006101', 'cytochrome P450 1A1', 95, 'CYP27B1'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 132, 'vitamin D metabolism')]
S109-PMC3476426	PMC3476426	8/2012	S109-PMC3476426	['autism was MORE COMMON among children of the mothers who took Antiepileptic Drugs AS these Drugs are one of the few classes of Drugs that CONSISTENTLY and SIGNIFICANTLY INTERFERE with Vitamin D Metabolism [39].']	[('PROBABLE_UNDERSTANDING', 11), ('PROBABLE_UNDERSTANDING', 82), ('PROBABLE_UNDERSTANDING', 138), ('IMPORTANT_CONSIDERATION', 155), ('SUPERFICIAL_RELATIONSHIP', 169)]	5	[('CHEBI_35218', 'anthocyanin cation', 62, 'antiepileptic'), ('CHEBI_23888', 'drug', 76, 'drugs'), ('CHEBI_23888', 'drug', 91, 'drugs'), ('CHEBI_23888', 'drug', 127, 'drugs'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 184, 'vitamin D metabolism'), ('PR_000006444', 'diacylglycerol kinase delta', 192, 'D')]
S29-PMC3613945	PMC3613945	2/2013	S29-PMC3613945	['Genotype-phenotype ASSOCIATIONS and Vitamin D Metabolism\nmature Serum dbp concentration is a quantitative trait with a significant hereditable component (66%), AS ESTABLISHED by twin studies published AT LEAST a decade ago30,31.']	[('SUPERFICIAL_RELATIONSHIP', 19), ('PROBABLE_UNDERSTANDING', 160), ('INCOMPLETE_EVIDENCE', 163), ('PROBABLE_UNDERSTANDING', 201)]	4	[('SO_0001026', 'genome', 0, 'Genotype'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 36, 'vitamin D metabolism'), ('UBERON_0001977', 'blood serum', 64, 'serum')]
S11-PMC3659910	PMC3659910	1/2013	S11-PMC3659910	['THIS REVIEW discusses Vitamin D Metabolism, dietary REQUIREMENTS and RECOMMENDATIONS and IMPLICATIONS of Vitamin D deficiency during Pregnancy and Lactation.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('IMPORTANT_CONSIDERATION', 52), ('FUTURE_WORK', 69), ('IMPORTANT_CONSIDERATION', 89)]	4	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 22, 'vitamin D metabolism'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('GO_0007565', 'female pregnancy', 133, 'pregnancy'), ('GO_0007595', 'lactation', 147, 'lactation')]
S68-PMC3717170	PMC3717170	5/2013	S68-PMC3717170	['Vitamin D during Pregnancy and Lactation\nVitamin D as a preprohormone has EFFECTS that extend beyond Calcium Metabolism and Homeostasis throughout Life but which are most vivid during Pregnancy when Vitamin D Metabolism is disengaged from its usual constraints.12at no other time during the Lifecycle is 25(Oh)D3Linked directly to 1,25(Oh)2d3production, the latter rising more than 2.5 times above nonpregnant levels.12this elevation of 1,25(oh)2d3likely serves the purpose of Immune Regulation, THOUGH there HAVE BEEN ONLY a FEW STUDIES that have evaluated the EFFECT of Vitamin D status on Immune function during Pregnancy to SUPPORT THIS HYPOTHESIS.']	[('SUPERFICIAL_RELATIONSHIP', 74), ('SUPERFICIAL_RELATIONSHIP', 484), ('ANOMALY_CURIOUS_FINDING', 496), ('INCOMPLETE_EVIDENCE', 509), ('INCOMPLETE_EVIDENCE', 519), ('INCOMPLETE_EVIDENCE', 526), ('SUPERFICIAL_RELATIONSHIP', 562), ('INCOMPLETE_EVIDENCE', 628), ('QUESTION_ANSWERED_BY_THIS_WORK', 636), ('INCOMPLETE_EVIDENCE', 641)]	10	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 17, 'pregnancy'), ('GO_0007595', 'lactation', 31, 'lactation'), ('CHEBI_28384', 'vitamin K', 41, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 41, 'Vitamin D'), ('GO_0018884', 'carbazole metabolic process', 101, 'calcium metabolism'), ('GO_0042592', 'homeostatic process', 124, 'homeostasis'), ('UBERON_0000104', 'life cycle', 147, 'life'), ('GO_0007565', 'female pregnancy', 184, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 199, 'vitamin D metabolism'), ('UBERON_0000104', 'life cycle', 291, 'lifecycle'), ('CHEBI_77914', '3-methylbut-1-ene', 304, '25(OH)D3linked'), ('CHEBI_63056', 'zinc cation', 333, '25(OH'), ('CHEBI_17996', 'chloride', 438, ','), ('GO_0002521', 'leukocyte differentiation', 477, 'immune regulation'), ('UBERON_0002405', 'immune system', 477, 'immune'), ('CHEBI_27300', 'vitamin D', 572, 'vitamin D'), ('UBERON_0002405', 'immune system', 592, 'immune'), ('GO_0007565', 'female pregnancy', 615, 'pregnancy')]
S129-PMC3717170	PMC3717170	5/2013	S129-PMC3717170	['li and colleagues have isolated Monocytes from patients and examined Expression of a number OF Genes RELATED to Vitamin D Metabolism and Immune Responses.']	[('ANOMALY_CURIOUS_FINDING', 92), ('SUPERFICIAL_RELATIONSHIP', 101)]	2	[('CL_0000576', 'monocyte', 32, 'monocytes'), ('GO_0010467', 'gene expression', 69, 'expression'), ('SO_0000704', 'gene', 95, 'genes'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 112, 'vitamin D metabolism'), ('GO_0006955', 'immune response', 137, 'immune responses'), ('UBERON_0002405', 'immune system', 137, 'immune')]
S205-PMC4045304	PMC4045304	2/2014	S205-PMC4045304	['heritability of autism MAY BE EXPLAINED by quantitative Genetic variations in SOME facet of Vitamin D Metabolism, such as vdr or in the enzymes that activate Vitamin D [86].']	[('INCOMPLETE_EVIDENCE', 23), ('PROBABLE_UNDERSTANDING', 30), ('INCOMPLETE_EVIDENCE', 78)]	3	[('SO_0000704', 'gene', 56, 'genetic'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 92, 'vitamin D metabolism'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D')]
S28-PMC4302429	PMC4302429	1/2015	S28-PMC4302429	['studies of the Innate Immune Response to pathogens such as mycobacterium tuberculosis HAVE SHOWN that pathogen-recognition receptor (prr)-mediated activation of localized Vitamin D Metabolism and signaling is a key event ASSOCIATED with resistance to infection [17].']	[('INCOMPLETE_EVIDENCE', 86), ('SUPERFICIAL_RELATIONSHIP', 221)]	2	[('GO_0045087', 'innate immune response', 15, 'innate immune response'), ('UBERON_0002405', 'immune system', 22, 'immune'), ('CHEBI_27300', 'vitamin D', 171, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 171, 'vitamin D metabolism')]
S2-PMC4303849	PMC4303849	1/2015	S2-PMC4303849	['THEREFORE, factors that Regulate Vitamin D Metabolism are of main IMPORTANCE, especially during Pregnancy.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 66)]	2	[('GO_0065007', 'biological regulation', 24, 'regulate'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 33, 'vitamin D metabolism'), ('GO_0007565', 'female pregnancy', 96, 'pregnancy')]
S65-PMC4499946	PMC4499946	7/2015	S65-PMC4499946	['Pregnant women are not enrolled if any of the following exclusion criteria apply: self-reported history of any medical condition or Medications that MAY predispose to Vitamin D sensitivity, altered Vitamin D Metabolism, and/or hypercalcemia (e.g., active tuberculosis or current therapy for tuberculosis, sarcoidosis, history of Renal and/or Ureteral stones, Parathyroid disease, Renal or Liver failure, or current use of antiseizure Medications); high-risk Pregnancy based on point-of-care (poc) testing (hemoglobin [hb]<70 g/l; proteinuria, defined as ≥300 mg/dl based on Urine dipstick; hypertension, defined as systolic Blood pressure ≥140 mmhg and/or diastolic Blood pressure ≥90 mmhg); high-risk Pregnancy based on maternal report and/or past ultrasound findings (multiple Gestation, major congenital anomaly, severe oligohydramnios); unwillingness to stop taking non-study Vitamin D or Calcium supplements or a multivitamins containing Calcium and/or Vitamin D; currently prescribed Vitamin D supplements as part of a physician’s treatment plan for Vitamin D deficiency; and/or previous enrollment in the mdig trial during a prior Pregnancy.']	[('INCOMPLETE_EVIDENCE', 149)]	1	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('CHEBI_25441', 'mycothiols', 132, 'medications'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 198, 'vitamin D metabolism'), ('UBERON_0002113', 'kidney', 329, 'renal'), ('UBERON_0000056', 'ureter', 342, 'ureteral'), ('UBERON_0001132', 'parathyroid gland', 359, 'parathyroid'), ('UBERON_0002113', 'kidney', 380, 'renal'), ('UBERON_0002107', 'liver', 389, 'liver'), ('CHEBI_25441', 'mycothiols', 434, 'medications'), ('GO_0007565', 'female pregnancy', 458, 'pregnancy'), ('UBERON_0001088', 'urine', 574, 'urine'), ('UBERON_0000178', 'blood', 624, 'blood'), ('UBERON_0000178', 'blood', 666, 'blood'), ('GO_0007565', 'female pregnancy', 702, 'pregnancy'), ('GO_0007565', 'female pregnancy', 779, 'gestation'), ('CHEBI_27300', 'vitamin D', 880, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 893, 'calcium'), ('CHEBI_22313', 'alkaline earth metal atom', 943, 'calcium'), ('CHEBI_27300', 'vitamin D', 958, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 990, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1056, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1138, 'pregnancy')]
S205-PMC4499946	PMC4499946	7/2015	S205-PMC4499946	['Genomic dna will be subjected to Bisulfite modification, and amplified Pcr Products will be analyzed by quantitative pyrosequencing to assess Dna Methylation at several consecutive Cpg Sites within an APPROXIMATELY 150-Bp region at the Promoters of two Genes INVOLVED in Vitamin D Metabolism ( Cyp27B1 and Cyp24A1 ).']	[('INCOMPLETE_EVIDENCE', 201), ('SUPERFICIAL_RELATIONSHIP', 259)]	2	[('SO_0001026', 'genome', 0, 'Genomic'), ('CHEBI_29874', 'bromine dioxide', 33, 'bisulfite'), ('SO_0000006', 'PCR_product', 71, 'PCR products'), ('GO_0006306', 'DNA methylation', 142, 'DNA methylation'), ('SO_0000036', 'matrix_attachment_site', 181, 'CpG sites'), ('SO_0000028', 'base_pair', 219, 'bp'), ('SO_0000167', 'promoter', 236, 'promoters'), ('SO_0000704', 'gene', 253, 'genes'), ('CHEBI_27300', 'vitamin D', 271, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 271, 'vitamin D metabolism'), ('PR_000006101', 'cytochrome P450 1A1', 294, 'CYP27B1'), ('PR_000006101', 'cytochrome P450 1A1', 306, 'CYP24A1')]
S284-PMC4499946	PMC4499946	7/2015	S284-PMC4499946	['the only clinical events that will routinely lead to discontinuation of study supplementation are those adverse events that are ascertained to be Supplement-related or the diagnosis of a medical condition that POTENTIALLY or THEORETICALLY increases sensitivity to Vitamin D supplementation following clinical review by the trial steering committee (tsc): confirmed hypercalcemia (see definition above), symptomatic Vitamin D deficiency diagnosed by a study physician or consultant physician (e.g., osteomalacia), fetal or infant death, or onset of a medical condition or initiation of a Medication following enrollment that MAY REASONABLY predispose to Vitamin D sensitivity, altered Vitamin D Metabolism, and/or hypercalcemia (e.g., tuberculosis or therapy for tuberculosis, sarcoidosis, Renal and/or Ureteral stones, Parathyroid disease, Renal or Liver failure, or use of Anticonvulsants).']	[('INCOMPLETE_EVIDENCE', 210), ('INCOMPLETE_EVIDENCE', 225), ('INCOMPLETE_EVIDENCE', 624), ('PROBABLE_UNDERSTANDING', 628)]	4	[('CHEBI_16158', 'steroid sulfate', 146, 'supplement'), ('CHEBI_27300', 'vitamin D', 264, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 415, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 423, 'D'), ('CHEBI_60211', 'compound Z', 587, 'medication'), ('CHEBI_27300', 'vitamin D', 653, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 684, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 684, 'vitamin D metabolism'), ('UBERON_0002113', 'kidney', 789, 'renal'), ('UBERON_0000056', 'ureter', 802, 'ureteral'), ('UBERON_0001132', 'parathyroid gland', 819, 'parathyroid'), ('UBERON_0002113', 'kidney', 840, 'renal'), ('UBERON_0002107', 'liver', 849, 'liver'), ('CHEBI_37540', 'arabinarate(2-)', 874, 'anticonvulsants')]
S53-PMC4934634	PMC4934634	11/2015	S53-PMC4934634	['vdr and enzymes NECESSARY for Vitamin D Metabolism HAVE BEEN FOUND in male Testis, mature Spermatozoa, and the Ejaculatory Tract SUGGESTING an IMPORTANT ROLE of this Vitamin in Male Fertility [19].']	[('IMPORTANT_CONSIDERATION', 16), ('INCOMPLETE_EVIDENCE', 51), ('INCOMPLETE_EVIDENCE', 129), ('IMPORTANT_CONSIDERATION', 143), ('SUPERFICIAL_RELATIONSHIP', 153)]	5	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 30, 'vitamin D metabolism'), ('UBERON_0000473', 'testis', 75, 'testis'), ('CL_0000019', 'sperm', 90, 'spermatozoa'), ('UBERON_0002649', 'dorsolateral fasciculus of medulla', 111, 'ejaculatory tract'), ('CHEBI_33229', 'vitamin (role)', 166, 'vitamin'), ('GO_0007141', 'male meiosis I', 177, 'male fertility')]
S169-PMC4971719	PMC4971719	8/2016	S169-PMC4971719	['this ASSOCIATION MAY BE ATTRIBUTED to a true EFFECT of nutritional deficiency OR ALTERNATELY MIGHT be RELATED to DIFFERENCES in Vitamin D Metabolism between women who are predisposed to depression and those who are not.']	[('SUPERFICIAL_RELATIONSHIP', 5), ('INCOMPLETE_EVIDENCE', 17), ('SUPERFICIAL_RELATIONSHIP', 24), ('SUPERFICIAL_RELATIONSHIP', 45), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 78), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 81), ('INCOMPLETE_EVIDENCE', 93), ('SUPERFICIAL_RELATIONSHIP', 102), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 113)]	9	[('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 128, 'vitamin D metabolism')]
S254-PMC5062906	PMC5062906	10/2016	S254-PMC5062906	['this is MOST LIKELY the result of Genetic DIFFERENCES in Vitamin D Metabolism and STUDIES are ONGOING to identify and characterize the loci responsible.']	[('PROBABLE_UNDERSTANDING', 8), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 42), ('INCOMPLETE_EVIDENCE', 82), ('IMPORTANT_CONSIDERATION', 94)]	4	[('SO_0000704', 'gene', 34, 'genetic'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 57, 'vitamin D metabolism')]
S118-PMC5084016	PMC5084016	10/2016	S118-PMC5084016	['IN FACT, ONLY the FIRST of the two Hydroxylation processes occurring in Vitamin D Metabolism (e.g., that responsible for the production of 25-Hydroxy-Vitamin D) is Modulated by the dietary contribution to SOME extent (the increase of circulating levels is not proportional to the amount Ingested).']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 9), ('INCOMPLETE_EVIDENCE', 18), ('INCOMPLETE_EVIDENCE', 205)]	4	[('GO_0044444', 'cytoplasmic part', 35, 'hydroxylation'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 72, 'vitamin D metabolism'), ('CHEBI_43141', '3-hydroxypropoxy group', 139, '25-hydroxy'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D'), ('GO_0065007', 'biological regulation', 164, 'modulated'), ('GO_0007631', 'feeding behavior', 287, 'ingested')]
S135-PMC5084016	PMC5084016	10/2016	S135-PMC5084016	['GIVEN the INFLUENCE of sunlight exposure on Vitamin D Metabolism, ATTENTION to ethnic groups with hyper-Pigmented skin or with little exposure to sunlight SHOULD BE paid also during Lactation.']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 10), ('FUTURE_WORK', 66), ('IMPORTANT_CONSIDERATION', 66), ('FUTURE_WORK', 155)]	5	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 44, 'vitamin D metabolism'), ('CHEBI_26130', 'biological pigment', 104, 'pigmented'), ('GO_0007595', 'lactation', 182, 'lactation')]
S110-PMC5085625	PMC5085625	9/2016	S110-PMC5085625	['owing the POTENTIAL CONTRIBUTION of an altered Vitamin D Metabolism to diabetes mellitus, we compared Serum concentrations of 25(Oh)D in patients with type 1 and 2 gdm (gdm g1 and gdm g2) and healthy controls.']	[('INCOMPLETE_EVIDENCE', 10), ('SUPERFICIAL_RELATIONSHIP', 20)]	2	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 47, 'vitamin D metabolism'), ('UBERON_0001977', 'blood serum', 102, 'serum'), ('CHEBI_71657', 'versiconol acetate', 126, '25(OH)D')]
S134-PMC5155676	PMC5155676	12/2016	S134-PMC5155676	['finally, during Pregnancy, a number OF physiological changes occur to Vitamin D Metabolism, including an increase in Vitamin D binding protein and 1,25-Dihydroxyvitamin d (15), indices that we were not able to include in our analysis.']	[('ANOMALY_CURIOUS_FINDING', 36)]	1	[('GO_0007565', 'female pregnancy', 16, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 70, 'vitamin D metabolism'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('CHEBI_72671', '(2S,3S)-versiconal hemiacetal acetate', 147, '1,25-dihydroxyvitamin')]
S61-PMC5372327	PMC5372327	3/2017	S61-PMC5372327	['we have studied gc polymorphisms in RELATION to Vitamin D Metabolism and bone strength in children [55] and OBSERVED differences in s-25-Ohd and pth concentrations between gc genotypes and that variation exists in bmd and bone strength index as well.']	[('SUPERFICIAL_RELATIONSHIP', 36), ('INCOMPLETE_EVIDENCE', 108)]	2	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 48, 'vitamin D metabolism'), ('CHEBI_72765', 'verruculogen', 134, '25-OHD')]
S16-PMC5405075	PMC5405075	4/2017	S16-PMC5405075	['it is, HOWEVER, INTERESTING that, during this period, Vitamin D Metabolism is shifted from the classical determinants of Calcium Homeostasis to OTHER Regulatory mechanisms.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 7), ('ANOMALY_CURIOUS_FINDING', 16), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 144)]	3	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 54, 'vitamin D metabolism'), ('GO_0055073', 'cadmium ion homeostasis', 121, 'calcium homeostasis'), ('GO_0065007', 'biological regulation', 150, 'regulatory')]
S93-PMC5405075	PMC5405075	4/2017	S93-PMC5405075	['a plethora of environmental and Genetic/epigenetic FACTORS CONTRIBUTE in a COMPLEX manner to a PARTLY understood pathogenesis, WHILE the shifted Vitamin D Metabolism during Pregnancy is also NOT FULLY ELUCIDATED.']	[('SUPERFICIAL_RELATIONSHIP', 51), ('SUPERFICIAL_RELATIONSHIP', 59), ('DIFFICULT_TASK', 75), ('INCOMPLETE_EVIDENCE', 95), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 127), ('INCOMPLETE_EVIDENCE', 191)]	6	[('SO_0000704', 'gene', 32, 'genetic'), ('CHEBI_27300', 'vitamin D', 145, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 145, 'vitamin D metabolism'), ('GO_0007565', 'female pregnancy', 173, 'pregnancy')]
S112-PMC5489519	PMC5489519	6/2017	S112-PMC5489519	['THEREFORE, IT IS POSSIBLE that elevated levels of Trail INFLUENCE Vitamin D Metabolism in Mammary Epithelial Cells45.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 56)]	3	[('PR_000001949', 'tumor necrosis factor ligand superfamily member 4', 50, 'TRAIL'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 66, 'vitamin D metabolism'), ('CL_0002327', 'mammary gland epithelial cell', 90, 'mammary epithelial cells45'), ('UBERON_0006954', 'mammary gland myoepithelium', 90, 'mammary epithelial')]
S12-PMC5546866	PMC5546866	8/2017	S12-PMC5546866	['abstract:teaser\nASSOCIATIONS between Snps in the Vitamin D Metabolism pathway and 25(Oh)D were ASSESSED before and after Antenatal Vitamin D supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 16), ('QUESTION_ANSWERED_BY_THIS_WORK', 95)]	2	[('SO_0000694', 'SNP', 37, 'SNPs'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 49, 'vitamin D metabolism'), ('PR_000006444', 'diacylglycerol kinase delta', 57, 'D'), ('CHEBI_71657', 'versiconol acetate', 82, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 88, 'D'), ('GO_0007567', 'parturition', 121, 'antenatal'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]
S19-PMC5546866	PMC5546866	8/2017	S19-PMC5546866	['in a PREVIOUS Genome-wide association study (gwas), we DEMONSTRATED that a NUMBER OF Single-Nucleotide Polymorphisms (Snps) in or near to Genes encoding KEY components of the Vitamin D Metabolism pathway are ASSOCIATED with Serum 25(Oh)D level (8).']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 55), ('INCOMPLETE_EVIDENCE', 75), ('IMPORTANT_CONSIDERATION', 153), ('SUPERFICIAL_RELATIONSHIP', 208)]	5	[('SO_0001026', 'genome', 14, 'genome'), ('SO_0000694', 'SNP', 85, 'single-nucleotide polymorphisms'), ('SO_0000694', 'SNP', 118, 'SNPs'), ('SO_0000704', 'gene', 138, 'genes'), ('CHEBI_27300', 'vitamin D', 175, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 175, 'vitamin D metabolism'), ('UBERON_0001977', 'blood serum', 224, 'serum'), ('CHEBI_71657', 'versiconol acetate', 230, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 233, 'OH ... D')]
S27-PMC5546866	PMC5546866	8/2017	S27-PMC5546866	['we THEREFORE undertook THIS STUDY TO DETERMINE WHETHER Snps within the Vitamin D Metabolism pathway KNOWN to modify Vitamin D status are also ASSOCIATED with the response to Antenatal Vitamin d supplementation.']	[('PROBABLE_UNDERSTANDING', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 23), ('QUESTION_ANSWERED_BY_THIS_WORK', 34), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 47), ('INCOMPLETE_EVIDENCE', 100), ('SUPERFICIAL_RELATIONSHIP', 142)]	6	[('SO_0000694', 'SNP', 55, 'SNPs'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 71, 'vitamin D metabolism'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('GO_0007567', 'parturition', 174, 'antenatal'), ('CHEBI_33229', 'vitamin (role)', 184, 'vitamin')]
S125-PMC5546866	PMC5546866	8/2017	S125-PMC5546866	['(11) (15 to 18 nmol/l) than our cohort (9 to 10 nmol/l), BUT this COULD REFLECT the higher Cholecalciferol doses used in those studies and/or alterations in Vitamin D Metabolism and volume of distribution in Pregnancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 57), ('INCOMPLETE_EVIDENCE', 66), ('SUPERFICIAL_RELATIONSHIP', 72)]	3	[('CHEBI_52550', 'theopalauamide', 91, 'cholecalciferol'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 157, 'vitamin D metabolism'), ('GO_0007565', 'female pregnancy', 208, 'pregnancy')]
S14-PMC5664622	PMC5664622	9/2017	S14-PMC5664622	['HOWEVER, OTHER authors CLAIM that maternal concentration that fully normalizes Vitamin D Metabolism and Calcium Homeostasis is AT LEAST 40 ng/ml [10], and still others that >20 ng/ml is NECESSARY to prevent Vitamin D deficiency in the newborn [11].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 9), ('INCOMPLETE_EVIDENCE', 23), ('PROBABLE_UNDERSTANDING', 127), ('IMPORTANT_CONSIDERATION', 186)]	5	[('CHEBI_27300', 'vitamin D', 79, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 79, 'vitamin D metabolism'), ('GO_0055073', 'cadmium ion homeostasis', 104, 'calcium homeostasis'), ('CHEBI_27300', 'vitamin D', 207, 'vitamin D')]
S122-PMC5812027	PMC5812027	2/2018	S122-PMC5812027	['WHETHER Vitamin D Metabolism is altered in Placental dysfunction in UNCLEAR and WARRANTS FURTHER INVESTIGATION.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FULL_UNKNOWN', 68), ('FUTURE_WORK', 80)]	3	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 8, 'vitamin D metabolism'), ('UBERON_0001987', 'placenta', 43, 'placental')]
S130-PMC5812027	PMC5812027	2/2018	S130-PMC5812027	['our results COULD also INDICATE that it takes time for changes in Vitamin D Metabolism to manifest as changes in circulating 25Ohd.']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 23)]	2	"[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 66, 'vitamin D metabolism'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 125, '25OHD')]"
S419-PMC5941617	PMC5941617	5/2018	S419-PMC5941617	['data on polymorphisms of OTHER Genes INVOLVED in Vitamin D Metabolism are still CONFLICTING or RELATED to small populations [373–376].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 25), ('SUPERFICIAL_RELATIONSHIP', 37), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 80), ('SUPERFICIAL_RELATIONSHIP', 95)]	4	[('SO_0000704', 'gene', 31, 'genes'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 49, 'vitamin D metabolism')]
S545-PMC5941617	PMC5941617	5/2018	S545-PMC5941617	['during Pregnancy Vitamin D Metabolism changes so that maternal Serum 1,25(Oh)2D levels significantly rise to meet increased calcium REQUIREMENTS for Fetal Skeleton mineralization, WHEREAS fetal Vitamin D stores are exclusively DEPENDENT on maternal Vitamin D status.']	[('IMPORTANT_CONSIDERATION', 132), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 180), ('SUPERFICIAL_RELATIONSHIP', 227)]	3	"[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 17, 'vitamin D metabolism'), ('UBERON_0001977', 'blood serum', 63, 'serum'), ('CHEBI_37958', 'dye', 69, '1,'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 71, '25(OH)2D'), ('UBERON_0000922', 'embryo', 149, 'fetal'), ('UBERON_0004288', 'skeleton', 155, 'skeleton'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 249, 'vitamin D')]"
S566-PMC5941617	PMC5941617	5/2018	S566-PMC5941617	['veiled women) and/or constant use of sunscreens• Malabsorption syndromes• chronic therapies AFFECTING Vitamin D Metabolism• obesity• risk of pre-eclampsia• Alcohol abuse• bone pain• hypocalcemia• a previous child with rickets• Pregnant adolescents\nin the present consensus we RECOMMEND Vitamin D supplementation in all Pregnant and breastfeeding women since the beginning of Pregnancy at a dose of 600\xa0iu/day.']	[('SUPERFICIAL_RELATIONSHIP', 92), ('FUTURE_WORK', 276)]	2	[('GO_0046661', 'male sex differentiation', 49, 'Malabsorption'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 102, 'vitamin D metabolism'), ('CHEBI_30879', 'alcohol', 156, 'Alcohol'), ('GO_0007565', 'female pregnancy', 227, 'Pregnant'), ('CHEBI_27300', 'vitamin D', 286, 'vitamin D'), ('GO_0007565', 'female pregnancy', 319, 'pregnant'), ('GO_0007565', 'female pregnancy', 375, 'pregnancy')]
S728-PMC5941617	PMC5941617	5/2018	S728-PMC5941617	['in subjects with asymptomatic Vitamin D deficiency assuming Drugs interfering with Vitamin D Metabolism (Anticonvulsants, oral Corticosteroids, antifungals like Ketoconazole, Anti-retroviral Drugs) we RECOMMEND Vitamin D treatment at higher doses THAN those RECOMMENDED for otherwise healthy pediatric population (AT LEAST 2000–4000\xa0iu/day), for a minimum of 6–8\xa0weeks.']	[('FUTURE_WORK', 201), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 247), ('FUTURE_WORK', 258), ('PROBABLE_UNDERSTANDING', 314)]	4	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('CHEBI_23888', 'drug', 60, 'drugs'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 83, 'vitamin D metabolism'), ('CHEBI_37540', 'arabinarate(2-)', 105, 'anticonvulsants'), ('CHEBI_50850', 'etabonate ester', 127, 'corticosteroids'), ('CHEBI_47519', 'ketoconazole', 161, 'ketoconazole'), ('CHEBI_59132', 'antigen', 175, 'anti'), ('CHEBI_23888', 'drug', 191, 'drugs'), ('CHEBI_27300', 'vitamin D', 211, 'vitamin D')]
S271-PMC5956785	PMC5956785	5/2018	S271-PMC5956785	['this review was UNABLE TO explore the RELATIONSHIP between Vitamin D status and ethnicity, Vitamin D receptor Genes or OTHER Genes that INFLUENCE Vitamin D Metabolism.']	[('DIFFICULT_TASK', 16), ('SUPERFICIAL_RELATIONSHIP', 38), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 119), ('SUPERFICIAL_RELATIONSHIP', 136)]	4	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('SO_0000704', 'gene', 110, 'genes'), ('SO_0000704', 'gene', 125, 'genes'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 146, 'vitamin D metabolism')]
S80-PMC6011374	PMC6011374	6/2018	S80-PMC6011374	['caption (table-wrap): table 2\n\nadjusted relative risks (arr) of Pregnancy complications from any complication, Preeclampsia (pe), Gestational hypertension (gh), Gestational diabetes mellitus (gdm), spontaneous Preterm Birth (sptb) and small-for-Gestational age (sga) according to Vitamin D status categorised based on standardised quartiles and clinical definitions of Vitamin D statuspregnancy complicationsall womenany complicationpeghgdmsptbsga n (%) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci)standardised quartiles**\u2003low711 (25)328 (46)0.95 (0.85, 1.07)46 (6)1.02 (0.66, 1.57))57 (8)0.97 (0.67, 1.42)28 (4)0.79 (0.47, 1.30)36 (5)0.83 (0.54, 1.29)84 (12)1.02 (0.75, 1.39)\u2003low-moderate755 (27)318 (42)1.00 (0.90, 1.12)42 (6)1.07 (0.69, 1.64)65 (9)1.06 (0.74, 1.52)25 (3)0.67 (0.39, 1.16)33 (4)0.87 (0.56, 1.3572 (10)0.98 (0.73, 1.32)\u2003moderate-high702 (25)309 (44)1.0†37 (5)1.0†50 (7)1.0†28 (4)1.0†39 (6)1.0†81 (12)1.0†\u2003high630 (23)258 (41)0.93 (0.82, 1.06)†35 (6)1.24 (0.78, 1.96)40 (6)0.87 (0.58, 1.30)10 (2) 0.47(0.23, 0.96) 30 (5)0.77 (0.48, 1.25)60 (10)0.80 (0.57, 1.11)Vitamin d status\u2003<25 nmol/l99 (4)51 (52)1.10 (0.89, 1.36)8 (8)1.44 (0.68, 3.03))6 (6)0.70 (0.32, 1.52)5 (5)0.98 (0.38, 2.52)7 (7)1.44 (0.68, 3.04)13 (13)1.15 (0.66, 2.01)\u200325-50 nmol/l673 (24)301 (45)0.93 (0.83, 1.03)45 (7)1.18 (0.80, 1.75)59 (9)0.97 (0.71, 1.34)26 (4)0.89 (0.54, 1.47)29 (4)0.75 (0.48, 1.16)74 (11)0.93 (0.69, 1.24)\u2003>50-75 nmol/l928 (33)428 (46)1.0†48 (5)1.0†80 (9)1.0†35 (4)1.0†52 (6)1.0†107 (12)1.0†\u2003>75 nmol/l1098 (39)435 (40)0.95 (0.86, 1.04)60 (5)1.28 (0.87, 1.87)67 (6)0.82 (0.59, 1.12)†26 (2)0.78 (0.48, 1.28)51 (5)0.86 (0.59, 1.26)104 (9)0.86 (0.67, 1.12)\n*relative risks compared to all women were adjusted for age, maternal body mass index, ethnicity (non caucasian vs. caucasian), smoking status at 15\u2009±\u20091\xa0weeks’ Gestation (no vs. yes), Alcohol consumption at 15\u2009±\u20091\xa0weeks’ (no vs yes), recreational walking (1-3×/week and\u2009≥\u20094×/week vs. never) and recruitment site (auckland vs. adelaide)\n**Serum 25(Oh)D was standardised for month that Serum was sampled based as previously described [34]\n†reference category\n\nSerum 25(Oh)D, Pregnancy outcome and fetal sex\nas THERE IS EVIDENCE to SUGGEST that Vitamin D Metabolism within the Placenta MAY DIFFER with respect to fetal sex [35] THUS, we ASSESSED the EFFECT of “standardised” Vitamin D status on Pregnancy outcome stratified by fetal sex (table\xa03).']	[('INCOMPLETE_EVIDENCE', 2230), ('INCOMPLETE_EVIDENCE', 2251), ('INCOMPLETE_EVIDENCE', 2305), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2309), ('PROBABLE_UNDERSTANDING', 2347), ('QUESTION_ANSWERED_BY_THIS_WORK', 2356), ('SUPERFICIAL_RELATIONSHIP', 2369)]	7	[('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 111, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 130, 'gestational'), ('GO_0007565', 'female pregnancy', 161, 'gestational'), ('GO_0007565', 'female pregnancy', 210, 'preterm birth'), ('GO_0007565', 'female pregnancy', 245, 'gestational'), ('CHEBI_27300', 'vitamin D', 280, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 369, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 1141, 'Vitamin'), ('GO_0007565', 'female pregnancy', 1882, 'gestation'), ('CHEBI_30879', 'alcohol', 1906, 'alcohol'), ('UBERON_0001977', 'blood serum', 2060, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 2066, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 2066, '25(OH)D'), ('UBERON_0001977', 'blood serum', 2106, 'serum'), ('UBERON_0001977', 'blood serum', 2180, 'Serum'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 2189, 'OH)D'), ('GO_0007565', 'female pregnancy', 2195, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 2264, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 2264, 'vitamin D metabolism'), ('UBERON_0001987', 'placenta', 2296, 'placenta'), ('CHEBI_27300', 'vitamin D', 2394, 'vitamin D'), ('GO_0007565', 'female pregnancy', 2414, 'pregnancy')]
